Compare iShares Core S&P 500 ETF (IVV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Sanofi SA — how do they compare? iShares Core S&P 500 ETF trades at $751.4, while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA pays a 5.5% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| IVV | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $763.10 | $52.34 |
52-Week Low | $624.65 | $41.33 |
Market Cap | — | $104.83B |
Enterprise Value | — | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $745.67, down 0.14% amid technical bearish signals and resistance at the 50-day moving average. The ETF faces valuation concerns with the Shiller CAPE ratio near historic highs. Recent institutional buying by Decker Wealth Management contrasts with broader market caution as earnings season progresses with mixed tech performance.
Outlook hinges on S&P 500 earnings resilience, particularly from tech giants, but overvaluation risks and sector concentration warrant caution. The bearish technical setup suggests near-term pressure, though long-term investors may find value in dollar-cost averaging given the index's historical track record.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
